Ultra-early STatin in Patients With Aneurysmal subaRachnoid Hemorrhage (Ue-STAR)

A researcher-initiated and conducted multicenter, randomized controlled trial aimed at evaluating the efficacy and safety of ultra-early statin therapy in the treatment of acute aneurysmal subarachnoid hemorrhage (aSAH).

Inclusion Criteria: 1. Male or female; Aged ≥18 years 2. Signs and symptoms presumed aneurysmal subarachnoid hemorrhage, confirmed by radiological evidence 3. Treatment within 6 h after symptom onset Exclusion Criteria: 1. Treatment with statin prior SAH 2. Non-aSAH (e.g. traumatic subarachnoid hemorrhage, arteriovenous malformation) 3. Treatment \> 6 h after symptom onset 4. Allergy to statin medications or presence of severe adverse reactions such as abnormal liver function or rhabdomyolysis 5. Evidence of irreversible brain damage or expected death within 7 days 6. Known severe liver or kidney disease 7. Non-compliance with follow-up 8. Pregnant or breastfeeding 9. History of severe cranial or psychiatric illness 10. Concomitant serious systemic disease 11. Patients with malignant tumors 12. Currently participating in another clinical trial 13. Considered unsuitable for the clinical trial by clinical physicians or researchers